Oncolytic Virus Therapy: Insights Into Clinical Trial Landscape And Industry Trends

Oncolytic virus (OV) therapy represents a promising cancer treatment modality, utilizing viruses to selectively target and destroy cancer cells while simultaneously stimulating the immune system. This approach has shown efficacy across various cancer types. The Asia-Pacific region, particularly China, is at the forefront of clinical trials, driven by a large patient population and streamlined processes, with North America and Europe also contributing significantly. Recent advancements in the field include the use of genetic engineering to enhance virus specificity and innovative delivery methods such as nanoparticle carriers.

Combining oncolytic viruses with other therapeutic strategies, notably immune checkpoint inhibitors, has demonstrated improved patient outcomes. Here, we answer several questions about OV therapies including how they integrate with combination therapies, the regulatory landscape for these therapies, and how it varies globally.